Skip to main content
GALECTIN THERAPEUTICS INC logo

GALECTIN THERAPEUTICS INC — Investor Relations & Filings

Ticker · GALT ISIN · US3632252025 LEI · 5299004HFYSAZM2ALW85 US Manufacturing
Open in API
Filings indexed 1,091 across all filing types
Latest filing 2014-02-05 Regulatory Filings
Country US United States of America
Listing US GALT

About GALECTIN THERAPEUTICS INC

https://galectintherapeutics.com/

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for fibrotic diseases, chronic liver disease, and cancer. The company's therapeutic approach centers on inhibiting the galectin-3 protein, which is implicated in various inflammatory, fibrotic, and malignant conditions. Its lead drug candidate, belapectin (GR-MD-02), is a proprietary carbohydrate-based drug designed to bind to and inhibit galectin-3. The primary development program for belapectin is focused on treating non-alcoholic steatohepatitis (MASH) with cirrhosis, a serious liver disease with no currently approved therapies.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated February 5, 2014, by Galectin Therapeutics Inc. It references posting a corporate presentation on the company's website containing a summary of the business. The document states that the presentation is being furnished and not filed, and the report is furnished under Item 7.01 Regulation FD Disclosure. There are no financial statements or substantive financial data included in the document. The length is 2984 characters, which is relatively short and mainly serves as an announcement of the corporate presentation being posted. According to the rules, such a document that announces the availability of a report or presentation but does not contain the report itself should be classified as Regulatory Filings (RNS), as it does not fit the criteria for an Investor Presentation (IP) or other report types. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2014-02-05 English
PRIMARY DOCUMENT
Director's Dealing
2014-02-04 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or press releases by a company. The text indicates that the filing includes an attached press release dated February 3, 2014. There are no financial statements or detailed financial data included in the text itself, only a reference to the press release. The document length is short (2289 characters), and it primarily serves as an announcement of the press release rather than the release of a full financial report or detailed data. According to the rules, such a document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and often include press release announcements in Form 8-K filings.
2014-02-03 English
PRIMARY DOCUMENT
Director's Dealing
2014-01-29 English
PRIMARY DOCUMENT
Director's Dealing
2014-01-29 English
PRIMARY DOCUMENT
Director's Dealing
2014-01-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.